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Introduction: Optic neuritis (ON) occurs in both multiple sclerosis (MS) and 
neuromyelitis optica (NMO), but is usually more severe in NMO. This study compared 
optic nerve magnetic transfer ratio (MTR) and retinal nerve fibre layer (RNFL) 
thickness, obtained with optic coherence tomography (OCT), of the affected and fellow 
eye between NMO and relapsing-remitting (RR) MS patients. In the patient groups, the 
relationships between MTR and OCT biomarkers and visual acuity (VA) were explored. 
Methods: 14 NMO and 3 NMOSD (spectrum disorder) patients (13F, mean age 
-6), 7 with unilateral and 5 bilateral ON), 12 RRMS 
-7.5), 5 with unilateral 
and 1 bilateral ON) and 21 healthy controls (HC) (
scanned at 3T and RNFL was measured on a Spectralis OCT. The MTR of the optic 
nerves were calculated and analysed using automated ROIs. VA was assessed in 
patients with letter charts and 100-hue test. Multiple linear regressions adjusted for age, 
gender and disease duration were used to compare MTR and OCT biomarkers 
between the different groups. 
Results: NMO patients showed lower MTR in the affected optic nerves than HC 
(regression coefficient (RC) -5.23, 95%CI -7.6, -2.87, p<0.001) and borderline 
evidence for lower MTR in the affected optic nerves than RRMS (RC -4.23, 95%CI -
9.17, 0.7, p=0.09). Similarly, NMO patients showed lower MTR in the fellow eye than 
HC (RC -2.18, 95%CI 4.56, -0.52, p=0.02) and RRMS (-2.67, 95%CI -4.78, -0.58, 
p=0.013). RRMS did not have a lower MTR in the affected and fellow eyes than HC. 
RNFL thickness in the affected eye was lower in RRMS than HC (RC -22.2, 95%CI -
39.1, -5.31, p=0.012) and in NMO than HC (RC -29.4, 95%CI -50.9, -7.9, p=0.009), but 
did not differ between NMO and RRMS. The RNFL thickness in the fellow eye did not 
differ between groups. 
In patients, the VA of the affected eye was associated with the corresponding optic 
nerve MTR (NMO: RC -0.12, p<0.001, MS: RC -0.04, p<0.001). This association was 
stronger in NMO patients (p<0.001). VA in the unaffected eye was associated with 
optic nerve MTR but only in MS (RC -0.04, p<0.001). 
Conclusion: Optic nerve MTR seems to distinguish between MS and NMO more 
effectively than OCT, though the use of OCT in NMO was limited by the low visual 
acuity of some patients. Optic nerve MTR is associated with visual acuity and could 
become a useful outcome measure for clinical trials in NMO. 
 
 
L. Magnollay, V. Wottschel, F. De Angelis, M. Yiannakas and Rosa Cortese have 
nothing to disclose. O. Ciccarelli receives research grant support from the Multiple 
Sclerosis Society of Great Britain and Northern Ireland, the Department of Health 
Comprehensive Biomedical Centre, the International Spinal Cord Research Trust 
(ISRT) and the Engineering and Physical Sciences Research Council (EPSRC); she 
serves as a consultant for Novartis, Biogen and GE and payments are made to UCL 
Institute of Neurology. A. Toosy has received speaker honoraria from Biomedia, 
Sereno Symposia International Foundation and Bayer. C. Tur received a McDonald 
Fellowship (from the Multiple Sclerosis International Federation) in 2007, and has 
received an ECTRIMS post-doctoral research fellowship in 2015. She has also 
received honoraria and support for travelling from Bayer-Schering, Teva, Merck-
Serono and Serono Foundation, Biogen, Sanofi-Aventis, Novartis, and Ismar 
Healthcare. D.H. Miller has received honoraria, through payments to UCL Institute of 
Neurology, for Advisory Committee and/or Consultancy advice in multiple sclerosis 
studies from Biogen Idec, GlaxoSmithKline, Novartis, Merck, Chugai, Mitsubishi 
Pharma Europe and Bayer Schering Pharma and has received compensation through 
payments to UCL Institute of Neurology for performing central MRI analysis of multiple 
sclerosis trials from GlaxoSmithKline, Biogen Idec, Novartis and Merck. 
 
 
